Atossa Therapeutics Inc. (NASDAQ: ATOS) stock gained by 30.09% at last close while the ATOS stock price rises by 4.83% in the after-hours trading session. Atossa Therapeutics is a clinical-stage biopharmaceutical business specializing on oncology and infectious illnesses, with a current emphasis on breast cancer and COVID-19.
Upcoming Important Event
ATOS will offer a webinar on June 9, 2021, to disclose and analyze final findings from its Phase 2 trial of Endoxifen given to breast cancer patients before surgery. Dr. Steven Quay, CEO and President, Kyle Guse, CFO, and General Counsel, and Dr. B. Heather Fraser, VP Clinical, Regulatory, and CMC, will participate in the webinar.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
Recent Past Development
Gilles Demaneuf, DRASTIC Investigator, and Dr. Steven C. Quay, Physician-Scientist and CEO of Atossa Therapeutics, have released a new study that examines if the assertion that there were no COVID cases at the Wuhan Institute of Virology (WIV) is true. Given that the WIV employed around 590 people at the time, and that the known frequency of COVID in Wuhan was 4.4 percent in the first half of 2020, it is statistically implausible that there were no instances.
Dr. Steven Quay, CEO of Atossa Therapeutics stated:
The goal of this investigation was to see if the reports from the United States could be reconciled. Early COVID instances were discovered in the autumn of 2019 at the Wuhan Institute of Virology, despite the WIV’s declarations that they had no cases. ATOS calculated that, with 4.4 percent of Wuhan’s general population testing positive around the same period, the chances of no one testing positive at the WIV are highly remote, unless the testing process was significantly defective and irrelevant. At the time of the WIV, Wuhan could not have had an island of uninfected individuals.
Investigator Gilles Demaneuf said,
The timeframe of early instances cannot be addressed directly in this investigation. Whether contaminated in the lab or in the community, well-structured testing of employees and students would have yielded a large number of positive cases.
